出版:
2023年11月6日
There is an increasing need to improve treatment approaches for people living with immune-mediated diseases who continue to face uncertain and unacceptable outcomes such as permanent organ damage, 不受控制的疾病活动甚至死亡.1-4
近年来， immunology has emerged as one of the fastest-growing fields of clinical research – second only to oncology – in terms of ongoing clinical trials.5
在澳门葡京网赌游戏, our ambition is to transform care for immune-mediated diseases by moving beyond symptom control to achieve disease modification, 缓解与, one day, 治愈全世界数百万人的疾病.
Following the science in immune-driven disease areas
Although clinical research in immunology is fast-growing, there remains a high unmet need for treatments for many people living with immune-mediated diseases who do not achieve disease control with existing therapies.3,6,7 Immune-mediated diseases occur when the immune system mistakenly attacks tissues in the body. 这种功能障碍会引起炎症, 在某些情况下还会造成永久性组织损伤, which can impact a wide range of body parts including the skin, joints, 肠道系统, kidneys, 肺和大脑.8
Our deep experience and scientific understanding of the immune system has led us to examine the impact of disease pathway imbalances across a number of conditions to help us understand the genetic drivers of disease. We are following the science to discover how we can intervene by resetting the activity within these key pathways, 减少炎症, repairing damaged tissue and stabilising the immune system.
Our bold ambition in immunology – to make remission a treatment goal
We are continuing to follow the science to further unlock our understanding of complex immune-driven diseases. Our bold ambition in Immunology is to disrupt current treatment paradigms and make remission – not just symptom management – a goal for as many patients as possible.
The current challenge for patients living with immune-mediated diseases
复杂的免疫介导疾病，比如 系统性红斑狼疮(SLE), eosinophilic granulomatosis with polyangiitis (EPGA) and inflammatory bowel disease (IBD) remain challenging to diagnose and treat, and many patients today do not achieve remission.1,3,9-11 例如，人们与 EGPA can often take more than four years to receive a diagnosis, and in lupus the path to diagnosis can be even longer (up to six years or more).1,12 对于这些病人, achieving disease control can be particularly challenging, and an estimated 10-15% will die prematurely due to lupus-related complications.1,9 Similarly, 高达50%的克罗恩病患者, IBD的一种, have no response to treatment and up to 80% fail to achieve remission.13
Despite the introduction of updated treatment strategies and the development of novel therapies in SLE and EGPA, oral corticosteroid (OCS) use still remains high.2,3,10 虽然OCS可以改善症状, long-term use is associated with poor quality of life and serious side effects, with an estimated 50% of patients with SLE developing irreversible organ damage within five years of diagnosis due to their disease and existing treatments.3,10,14-16 克罗恩病, studies have shown that the use of OCS works well to reduce and control symptoms during flare-ups, but may not be as effective in achieving lasting remission.17
Treatment goals for the future of immune-mediated diseases
Remission is a treatment goal in guidelines for SLE, EGPA和IBD, including Crohn’s disease and ulcerative colitis (UC).
SLE
The recently updated international SLE treatment recommendations from the European Alliance of Associations for 风湿病学 (EULAR) emphasise the need for prompt initiation of treatment aiming at remission, which is associated with improved clinical outcomes including reduced organ damage, 更少的耀斑, 减少住院, reduced mortality and improved health-related quality of life.9,18,19 The revised SLE treatment recommendations advise an OCS-sparing approach (a threshold of 5mg per day or less) to significantly reduce disease progression and improve quality of life for patients.16
EGPA
Similarly, treatment of EGPA is focused on preventing relapses and increasing the time spent in remission, as the number of relapses and duration of OCS use are associated with long-term organ damage.20,21 Global EGPA guidelines recognise both inducing and maintaining remission as a treatment goal and recommend that OCS use is kept to a minimum.22,23
IBD
Finally, the aim of IBD treatment for both Crohn’s disease and UC is to induce and maintain remission. While European Crohn’s and Colitis Organisation (ECCO) guidelines consider OCS effective in inducing remission, they note use-limiting adverse events and the inability to prevent disease relapse.24 随着更多治疗方法的出现, it may be possible to use targets based on objective measures to work toward effective and lasting disease control.25
越来越多的证据正在浮出水面, 包括其他慢性病的例子, that could further inform guidelines to drive greater adoption of OCS-sparing strategies and enable physicians to safely and effectively taper their patients from OCS.
Patients living with immune-mediated diseases deserve improved outcomes and sustained relief. We hope to unlock opportunities to better target these conditions, 导致新的治疗方法, and through earlier intervention and personalised medicine, ultimately change the natural course of these diseases.
Shifting mindsets and implementing the latest treatment recommendations could bring clinical practice closer to other disease areas that have had success, and, ultimately, make a significant impact on the long-term health of people living with chronic immune-driven diseases. 在澳门葡京网赌游戏, we won’t stop until we deliver clinical remission for the majority of those living with these complex diseases.
你可能也喜欢
References
1. 美国狼疮基金会. 狼疮的事实和统计. 可以在: http://www.lupus.org/resources/lupus-facts-and-statistics [最后访问日期:2023年10月].
2. Diane Apostolopoulos, Eric F. Morand, It hasn’t gone away: the problem of glucocorticoid use in lupus remains, 风湿病学, Volume 56, Issue suppl_1, April 2017, Pages i114–i122, http://doi.org/10.1093/rheumatology/kew406 [最后访问日期:2023年10月]
3. 张建军，张建军，张建军. Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States. J管理护理规范药房. 2021年9月,27 (9):1249 - 1259. doi: 10.18553/jmcp.2021.21002.
4. 美国嗜酸性疾病合作组织. Eosinophilic Granulomatosis with Polyangiitis (EGPA). 可以在: http://apfed.org/about-ead/eosinophilic-granulomatosis-with-polyangiitis/. [最后访问日期:2023年10月].
5. Leven, T, Norton M, Vaidyanathan S.改善免疫介导疾病的护理. 访问: http://www.bcg.com/publications/2022/improving-research-and-development-in-pharma-industry-for-immune-mediated-diseases [最后访问日期:2023年10月].
6. Medscape. 系统性红斑狼疮(SLE). 可以在: http://emedicine.medscape.com/article/332244-overview [最后访问日期:2023年10月]
7. Olesińska M，等. Quality of life in systemic lupus erythematosus and its measurement. Reumatologia. 2018; 56 (1): 45-54.
8. National Institute of Arthritis and Musculoskeletal and Skin Diseases. 系统性红斑狼疮(狼疮). 最后回顾2022年10月. 于2024年5月6日发布. http://www.niams.nih.gov /健康话题/狼疮.
9. Ugarte-Gil MF, et al. Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review. 狼疮科学医学. 2021;8:e000542. doi: 10.1136 /狼疮- 2021 - 000542
10. Baldini C，等. Clinical Manifestations and Treatment of Churg-Strauss Syndrome. Rheum Dis clinn Am. 2010:36;527–543.
11. 韦氏我, et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. [英]医学. 2017:376;1921-1932.
12. 穆西格F，等. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): 150例患者的单中心体验. Ann Rheum Dis. 2013;72:1011-1017.
13. Kayal M，等. Net Remission Rates with Biologic Treatment in Crohn's Disease: A Reappraisal of the Clinical Trial Data. 【澳门葡京赌博游戏】胃肠醇肝醇. 2023; 21 (5): 1348 - 1350.
14. Segura BT等. Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort. Rheumatol. 2020; 59 (3): 524-533.
15. Ugarte-Gil MF，等. Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. 狼疮科学医学. 2021; 8 (1): e000590.
16. Bruce IN，等. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the systemic lupus international collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2015; 74: 1706-1713.
17. Crohn's & Colitis UK. Steroids. 最后审查2023年3月. 于2024年5月6日发布. http://crohnsandcolitis.org.uk/info-support/information-about-crohns-and-colitis/all-information-about-crohns-and-colitis/treatments/steroids#:~:text=You%20may%20have%20steroids%20when,% 20需要% 20标准% 20口服% 20类固醇.
18. Fanouriakis, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 首次在线发布:2023年10月12日. doi: 10.1136 / ard - 2023 - 224762.
19. Kandane-Rathnayake R, et al. Lupus low disease activity state and 缓解与 risk of mortality in patients with systemic lupus erythematosus: a prospective, 跨国公司, 纵向队列研究. 柳叶刀Rheumatol. 2022;4(12):e822-e830.
20. Raffray L等. Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review. Drugs. 2018年6月,78 (8):809 - 821
21. 罗布森J，等. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. 风湿病学. 2015年3月,54 (3):471 - 81
22. 钟莎，等. 2021 American College of 风湿病学/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. 关节炎Rheumatol. 2021年8月,73 (8):1366 - 1383.
23. Hellmich B等. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2023年3月:ard - 2022 - 223764.
24. 张志军，等. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. 克罗恩性结肠炎. 2020年1月1日;14(1):4-22.
25. Lamb CA，等. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019 Dec;68(增刊3):s1-s106.
Veeva ID: Z4-65791
筹备日期:2024年6月